Posted by Michael Wonder on 05 Dec 2021
FDA approves new Kyprolis (carfilzomib) combination regimen with Darzalex Faspro (daratumumab and hyaluronidase-fihj) and dexamethasone for patients with multiple myeloma at first or subsequent relapse
1 December 2021 - Kyprolis in combination with subcutaneous treatment regimen provides further options and convenience for patients with relapsed/refractory multiple myeloma.
Amgen today announced that the U.S. FDA has approved the expansion of the Kyprolis (carfilzomib) U.S. Prescribing Information to include its use in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
